Pharmesis H1 revenue falls 56% amid challenging operating environment

Pharmesis International

14/08/2026 12:16

Overview
Pharmaceutical firm's first-half revenue fell sharply yr/yr, gross profit declined 61%
Loss for the period widened sharply amid higher administrative costs and lower sales
Gross margin for the first half was 34%

Outlook
Company did not provide specific financial outlook

Result Drivers
REVENUE DROP - Revenue fell 56.4% yr/yr; financial performance materially impacted by a challenging operating environment
HIGHER ADMINISTRATIVE COSTS - Administrative costs rose 7% yr/yr, contributing to wider losses

Company press release: ID:nSN3xV213

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Gross Margin
 
34.00%
 

Analyst Coverage
The stock recently traded at 2 times the next 12-month earnings vs. a P/E of 6 three months ago

Reuters Recommended Reads
Aug 12 - Hong Kong's Qianhai Health interim revenue falls on supply constraints
Aug 13 - China's JD Health interim revenue rises on user growth, product expansion
Aug 12 - Medicus Pharma Q2 net loss widens as operating expenses rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)